the present invention relates to pharmaceutical formulations ARN - 509, satisfied with the possibility of \u043c\u043b\u0435\u043a\u043e\u043f\u0438\u0442\u0430\u044e\u0449\u0435\u043c\u0443, in particular a man suffering \u0437\u0430\u0431\u043e\u043b\u0435\u0432 \u0430\u043d\u0438\u0435\u043c or condition associated with \u0430\u043d\u0434\u0440\u043e\u0433\u0435\u043d\u043e\u0432\u044b\u043c \u0440\u0435\u0446\u0435\u043f\u0442\u043e\u0440\u043e\u043c (ar), in particular cancer, specifically prostate cancer, including, without limitation, \u043a\u0430\u0441\u0442\u0440\u0430\u0446\u0438\u043e\u043d\u043d\u043e - re \u0437\u0438\u0441\u0442\u0435\u043d\u0442\u043d\u044b\u0439 prostate cancer.\u043a\u0430\u0441\u0442\u0440\u0430\u0446\u0438\u043e\u043d\u043d\u043e - \u0440\u0435\u0437\u0438\u0441\u0442\u0435\u043d\u0442\u043d\u044b\u0439 metastatic prostate cancer, not previously singled chemotherapy of metastatic cancer \u043f\u0440\u0435\u0434\u0441 \u043a\u0430\u0441\u0442\u0440\u0430\u0446\u0438\u043e\u043d\u043d\u043e - \u0440\u0435\u0437\u0438\u0441\u0442\u0435\u043d\u0442\u043d\u044b\u0439 \u0442\u0430\u0442\u0435\u043b\u044c\u043d\u043e\u0439 glands, biochemically \u0440\u0435\u0446\u0438\u0434\u0438\u0432\u0438\u0440\u0443\u044e\u0449\u0438\u0439 \u0433\u043e\u0440\u043c\u043e\u043d\u043e\u0447\u0443\u0432\u0441\u0442\u0432\u0438\u0442\u0435\u043b\u044c\u043d\u044b\u0439 prostate cancer or a high risk of \u043d\u0435\u043c\u0435\u0442\u0430\u0441\u0442\u0430\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043a\u0430\u0441\u0442\u0440\u0430\u0446 ion \u0440\u0435\u0437\u0438\u0441\u0442\u0435\u043d\u0442\u043d\u044b\u0439 prostate cancer.in one aspect, these compositions contain solid dispersion ARN - 509, copolymer of poly (meth) \u0430\u043a\u0440\u0438\u043b\u0430\u0442\u0430 and HPMCAS.in one aspect, solid dispersion ARN - 509, copolymer of poly (meth) \u0430\u043a\u0440\u0438\u043b\u0430\u0442\u0430 and HPMCAS can receive, such as receiving, by means
